Vladimir Ynse Ieuwe Gerardus Tichelaar

Vladimir Ynse Ieuwe Gerardus Tichelaar

Auto-generated profile, based on publicly available information

Vladimir Ynse Ieuwe Gerardus Tichelaar

Department of Haematology, University Medical Center Groningen, University of Groningen , Hanzeplein 1, Groningen 9713 GZ, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MTMyrthe M A Toorop
Myrthe M A Toorop
QCQingui Chen
Qingui Chen
VTVladimir Y I G Tichelaar
Vladimir Y I G Tichelaar
SCSuzanne C Cannegieter
Suzanne C Cannegieter
WLWillem M Lijfering
Willem M Lijfering
Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied. We investigated the persistence with oral anticoagulants (OACs) and its association with prognosis among a nationwide cohort of NVAF patients. DOAC-naive NVAF patients who started to use DOACs for ischaemic stroke prevention between 2013 and 2018 were included using Dutch national statistics. Persistence with OACs was determined based on the presence of a 100-day gap between the last prescription and the end of study period. In 93 048 patients, 75.7% had a baseline CHA2DS2-VASc score of ≥2. The cumulative incidence of persistence with OACs was 88.1% [95% confidence interval (CI) 87.9–88.3%], 82.6% (95% CI 82.3–82.9%), 77.7% (95% CI 77.3–78.1%), and 72.0% (95% CI 71.5–72.5%) at 1, 2, 3, and 4 years after receiving DOACs, respectively. Baseline characteristics associated with better persistence with OACs included female sex, age range 65–74 years, permanent atrial fibrillation, previous exposure to vitamin K antagonists, stroke history (including transient ischaemic attack), and a CHA2DS2-VASc score ≥2. Non-persistence with OACs was associated with an increased risk of the composite outcome of ischaemic stroke and ischaemic stroke-related death [adjusted hazard ratio (aHR) 1.79, 95% CI 1.49–2.15] and ischaemic stroke (aHR 1.58, 95% CI 1.29–1.93) compared with being persistent with OACs. At least a quarter of NVAF patients were non-persistent with OACs within 4 years, which was associated with poor efficacy of ischaemic stroke prevention. The identified baseline characteristics may help identify patients at risk of non-persistence.

14 May 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
Casper RokxCasper Rokx
Casper Rokx
JHJaime F. Borjas Howard
Jaime F. Borjas Howard
CSColette Smit
Colette Smit
FWFerdinand W. Wit
Ferdinand W. Wit
EPElise D. Pieterman
Elise D. Pieterman
OCOn Behalf Of The Athena Observational Hiv Cohort
On Behalf Of The Athena Observational Hiv Cohort
Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population. PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003–2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999–2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23–2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04–2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm3 increase, 95% CI 0.67–0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period. Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE.

28 June 2018 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Open access
PDF file
KLKarina de Leeuw
Karina de Leeuw
ARAbraham Rutgers
Abraham Rutgers
KMKarina Meijer
Karina Meijer
VTVladimir Ynse Ieuwe Gerardus Tichelaar
Vladimir Ynse Ieuwe Gerardus Tichelaar
JBJaime Francisco Borjas-Howard
Jaime Francisco Borjas-Howard
Despite an abundance of literature on the risk of a first venous thromboembolic event (VTE) in autoimmune diseases, specific recommendations about managing VTE in autoimmune diseases are lacking. This article aimed to collect evidence on the risk of recurrent VTE in patients with autoimmune diseases. The authors searched PubMed/Embase for studies including patients with VTE and autoimmune diseases as an exposure or studies including patients with autoimmune diseases in which recurrent VTE was one of the outcomes. Eleven articles were selected from 4,739 unique abstracts. Of the 11 studies, 3 reported time-dependent rates. Two studies collected rates of recurrence in Behcet's disease, reporting a 5-year recurrence risk between 35 and 40%. However, the 5-year recurrence risk was lower than 10% in patients treated with immunosuppressant medication, while two studies suggested frequent recurrence in patients on only anticoagulant therapy. The other study reporting time-dependent incidence concerned patients with inflammatory bowel disease and index VTE. The 5-year risk of recurrent VTE was 33.4%, yielding a hazard ratio of 1.7 versus controls. All studies were retrospective and therefore risk may overestimate recurrence risk in comparison with known prospective cohort studies. There are insufficient data to make confident recommendations about the management of recurrent VTE prevention in patients with autoimmune diseases in general. The overall VTE risk profile, lower effectiveness of anticoagulants, and the observation that immunosuppression lowered risk of recurrence in patients with Behcet's disease seem to warrant immunosuppressant therapy over anticoagulation as a first consideration when preventing VTE recurrence in these patients.

1 September 2020 in Thrombosis Research
Verified
Journal Article
Open access
JBJaime F. Borjas-Howard
Jaime F. Borjas-Howard
SBSoerajja Bhoelan
Soerajja Bhoelan
JMJasper van Miert
Jasper van Miert
RERuben J. Eck
Ruben J. Eck
HKHilde A.M. Kooistra
Hilde A.M. Kooistra
VTVladimir Y.I.G. Tichelaar
Vladimir Y.I.G. Tichelaar

13 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TETessa Elling
Tessa Elling
NVNic Veeger
Nic Veeger
SWSelma Waaijers
Selma Waaijers
AKAdrian Kruit
Adrian Kruit
JPJos G.J. Pouwels
Jos G.J. Pouwels
KMKarina Meijer
Karina Meijer
BackgroundRegular international normalized ratio (INR) monitoring is essential for maintaining optimal anticoagulation intensity in vitamin K antagonist (VKA)-treated patients. Unforeseen circumstances, such as the COVID-19 pandemic, led to temporary adjustments in regional anticoagulation clinic protocols, potentially reducing INR testing frequency and affecting INR control. We evaluated whether these adjustments resulted in increased INR intervals and whether this impacted INR control. MethodsAll patients managed by four Dutch Anticoagulation services were included in a dynamic cohort (December 2018 to December 2020). The study was divided into eight quartiles, with inclusion criteria assessed at the start of each quartile. INR return interval and INR control (time under/in/above the therapeutic range, INR variability, mean INR and proportion of high INR values) were calculated per quartile. Pandemic and pre-pandemic periods were compared, referencing the previous year.ResultsOver 23,000 patients were included per quartile (mean age 80 years, 55% male). In each quartile, 52.7-56.0% of the patients maintained therapeutic range (TTR) above 70%. INR return interval increased during the pandemic, especially at the start (28.0 [IQR 19.3-38.5] vs. 25.1 [IQR 16.3-32.7] days, p-value < 0.001). No decrease in TTR was observed. Instead, a slight numerical increase occurred (72.8 [IQR 51.1-100.0] vs. 75.0 [IQR 54.4-100.0], p-value <0.01). Other INR control measures showed similar stability. ConclusionCompared to the pre-pandemic period, INR testing frequency decreased during the COVID-19 pandemic due to temporary protocol adjustments. However, INR control was not negatively affected. In conclusion, VKA therapy is not immediately compromised when circumstances mandate a reduced INR testing frequency.